DC vaccine + TLR agonists

DC vaccine + TLR agonists is a therapeutic cancer vaccine strategy that combines autologous or allogeneic dendritic cell (DC) vaccines with toll-like receptor (TLR) agonists. The dendritic cell vaccine serves as an antigen-presenting platform engineered to stimulate robust, tumor-specific immune responses by presenting tumor antigens to T cells. TLR agonists (such as poly-ICLC, resiquimod, imiquimod, Rv2299c, and CpG oligonucleotides) act as adjuvants that activate innate immunity by binding to and stimulating specific TLRs on dendritic cells, leading to their maturation and improved function. The resulting synergy enhances both cellular (CD4+, CD8+ T cells, NK cells) and humoral immunity, polarizes Th1 immune responses, and can reinvigorate antitumor immunity even in immunosuppressive tumor microenvironments. This combination shows promise in clinical trials, particularly for malignancies like glioma, other solid tumors, and infectious diseases such as hepatitis C, with observed improvements in immune activation, tumor control, and in some cases, overall survival[1][2][3][7][8][9].